Celsion Reveals Positive Interim Data From Ph 2 DIGNITY Trial In Breast Cancer

(RTTNews) - Celsion Corp. (CLSN) on Thursday announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer.

The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Based on data available to date, a local response rate of 80% has been observed in the 5 evaluable patients with refractory disease, notably 2 complete responses, 2 partial responses and 1 patient with stable disease.

The data are consistent with the previously reported positive Phase 1 data in RCWBC.